|
|
|
|
|
|
|
|
abstract
Taxanes (docetaxel and
paclitaxel) are among the most commonly prescribed anticancer drugs
approved for the treatment of metastatic or locally advanced breast,
non-small cell lung, prostate, gastric, head and neck, and ovarian
cancers, as well as in the adjuvant setting for operable node-positive
breast cancers. Although the true incidence of dermatological adverse
events (AEs) in patients receiving taxanes is not known, and has never
been prospectively analysed, they clearly represent one of the major AEs
associated with these agents. With an increase in the occurrence of
cutaneous AEs during treatment with novel targeted and immunological
therapies when used in combination with taxanes, a thorough
understanding of reactions attributable to this class is imperative.
Moreover, identification and management of dermatological AEs is
critical for maintaining the quality of life in cancer patients and for
minimizing dose modifications of their antineoplastic regimen. This
analysis represents a systematic review of the dermatological conditions
reported with the use of these drugs, complemented by experience at
comprehensive cancer centres. The conditions reported herein include
skin, hair, and nail toxicities. Lastly, we describe the dermatological
data available for the new, recently FDA-and EMA- approved, solvent-free
nab-paclitaxel.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.